FDA Workshop: Opportunities to Improve Dose Optimization: Designing Trials and Applying Pharmacometrics
*May 2022* EGFR Resisters co-founder Jill Feldman participated as a panelist in this FDA Oncology Workship: 3a "Opportunities to Improve Dose Optimization: Designing Trials and Applying Pharmacometrics; and 3b "Opportunities to Improve Dose Optimization: Assessing Safety and Tolerability." Current strategies for determining the recommended dose(s) of anticancer agents for evaluation…
laurabbook@gmail.comJuly 3, 2022












